ChemicalBook > CAS DataBase List > Ataciguat
Ataciguat
- Product Name
- Ataciguat
- CAS No.
- 254877-67-3
- Chemical Name
- Ataciguat
- Synonyms
- HMR 1766;Ataciguat;Ataciguat (HMR-1766;5-Chloro-2-(5-chlorothiophene-2-sulfonamido)-N-(4-(morpholinosulfonyl)phenyl)benzamide;5-Chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide;Benzamide, 5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]-;cyclase,soluble,HMR 1766,Ataciguat,Guanylate Cyclase,Inhibitor,sGC,inhibit,HMR1766,vasodilator,cGMP,guanylate
- CBNumber
- CB41565384
- Molecular Formula
- C21H19Cl2N3O6S3
- Formula Weight
- 576.5
- MOL File
- 254877-67-3.mol
More
Less
Ataciguat Property
- Density
- 1.613±0.06 g/cm3(Predicted)
- solubility
- DMF: 1 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml
- form
- A crystalline solid
- pka
- 5.70±0.50(Predicted)
- color
- White to off-white
More
Less
N-Bromosuccinimide Price
Cayman Chemical
- Product number
- 16371
- Product name
- Ataciguat
- Purity
- ≥95%
- Packaging
- 1mg
- Price
- $81
- Updated
- 2024/03/01
Cayman Chemical
- Product number
- 16371
- Product name
- Ataciguat
- Purity
- ≥95%
- Packaging
- 5mg
- Price
- $356
- Updated
- 2024/03/01
Cayman Chemical
- Product number
- 16371
- Product name
- Ataciguat
- Purity
- ≥95%
- Packaging
- 10mg
- Price
- $632
- Updated
- 2024/03/01
TRC
- Product number
- A790040
- Product name
- Ataciguat
- Packaging
- 5mg
- Price
- $290
- Updated
- 2021/12/16
Biosynth Carbosynth
- Product number
- FA18005
- Product name
- Ataciguat
- Packaging
- 5mg
- Price
- $175
- Updated
- 2021/12/16
More
Less
Ataciguat Chemical Properties,Usage,Production
Uses
Ataciguat, formerly referred to as HMR-1766, a novel anthranilic acid derivative, belongs to a new structural class of sGC activators capable of activating the oxidized form of sGC. Ataciguat has been shown to improve endothelial function and to reduce platelet activation in exptl. diabetes. Chronic regular treatment with sGC activators such as ataciguat could therefore eventually constitute an effective therapy targeting deficient NO/cGMP signaling in hypertension, peripheral and coronary artery disease, heart failure, thrombosis and erectile dysfunction.